236 related articles for article (PubMed ID: 21712284)
1. Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease.
Schaer B; Sticherling C; Szili-Torok T; Osswald S; Jordaens L; Theuns DA
Europace; 2011 Nov; 13(11):1562-7. PubMed ID: 21712284
[TBL] [Abstract][Full Text] [Related]
2. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
[TBL] [Abstract][Full Text] [Related]
5. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
6. Effect of implantable cardioverter-defibrillator on left ventricular ejection fraction in patients with idiopathic dilated cardiomyopathy.
Schaer B; Theuns DA; Sticherling C; Szili-Torok T; Osswald S; Jordaens L
Am J Cardiol; 2010 Dec; 106(11):1640-5. PubMed ID: 21094367
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function.
Schaer BA; Ammann P; Sticherling C; Zellweger MJ; Cron TA; Osswald S
Int J Cardiol; 2006 Mar; 108(1):26-30. PubMed ID: 16516695
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction.
Clementy N; Pierre B; Lallemand B; Marie O; Lemoine E; Cosnay P; Fauchier L; Babuty D
Europace; 2012 Jul; 14(7):968-74. PubMed ID: 22389416
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter defibrillator therapy activation for high risk patients with relatively well preserved left ventricular ejection fraction. Does it really work?
Gatzoulis KA; Tsiachris D; Dilaveris P; Archontakis S; Arsenos P; Vouliotis A; Sideris S; Trantalis G; Kartsagoulis E; Kallikazaros I; Stefanadis C
Int J Cardiol; 2013 Aug; 167(4):1360-5. PubMed ID: 22534047
[TBL] [Abstract][Full Text] [Related]
11. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
[TBL] [Abstract][Full Text] [Related]
12. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study).
Nombela-Franco L; Mitroi CD; Fernández-Lozano I; García-Touchard A; Toquero J; Castro-Urda V; Fernández-Diaz JA; Perez-Pereira E; Beltrán-Correas P; Segovia J; Werner GS; Javier G; Luis AP
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):147-54. PubMed ID: 22205684
[TBL] [Abstract][Full Text] [Related]
13. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological study and 'slow' ventricular tachycardia predict appropriate therapy: results from a single-centre implantable cardiac defibrillator follow-up.
Worck R; Haarbo J; Thomsen PE
Europace; 2007 Nov; 9(11):1048-53. PubMed ID: 17686794
[TBL] [Abstract][Full Text] [Related]
15. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
[TBL] [Abstract][Full Text] [Related]
17. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
[TBL] [Abstract][Full Text] [Related]
18. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score.
van Rees JB; Borleffs CJ; van Welsenes GH; van der Velde ET; Bax JJ; van Erven L; Putter H; van der Bom JG; Schalij MJ
Heart; 2012 Jun; 98(11):872-7. PubMed ID: 22581736
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
[TBL] [Abstract][Full Text] [Related]
20. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
